查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1997277

早產和胎膜早破檢測市場：按產品類型、技術、生物標記、最終用戶和應用分類－2026-2032年全球市場預測

Preterm Birth & PROM Testing Market by Product Type, Technology, Biomarker, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，早產和胎膜早破 (PROM) 檢測市場價值將達到 14.6 億美元，到 2026 年將成長到 15.4 億美元，到 2032 年將達到 21.4 億美元，年複合成長率為 5.62%。

主要市場統計數據
基準年 2025 14.6億美元
預計年份：2026年 15.4億美元
預測年份 2032 21.4億美元
複合年成長率 (%) 5.62%

動態實施臨床優先事項、診斷工作流程和營運挑戰，進而影響醫療保健機構中早產和胎膜早破檢測。

早產和胎膜早破 (PROM) 的檢測處於產科、新生兒護理和診斷技術創新的交叉領域。臨床醫生越來越依賴客觀的生物標記和改進的檢測流程來做出影響母嬰結局的時效性決策。同時，實驗室主任和採購團隊面臨越來越大的壓力，需要在將新平台整合到現有診斷系統的同時，平衡準確性、檢測能力和成本。

近期技術進步、實證方法和供應鏈變化如何重塑檢測早產風險和胎膜早破的診斷策略。

近年來，早產風險和胎膜早破（PROM）風險的識別、監測和管理發生了變革性變化。分子診斷、免疫檢測和照護現場技術的進步，使得檢測結果的快速出具在不影響分析性能的前提下得以實現。同時，透過數位健康平台和檢查室資訊系統（LIS）實現的更完善的數據整合，使臨床醫生能夠將生物標記結果與電子健康記錄趨勢和決策支援演算法相結合。這些進步共同提高了臨床醫生對快速且可操作的診斷結果的期望。

了解 2025 年關稅政策變更和進口成本壓力將如何影響診斷測試供應鏈的韌性、籌資策略和部署計畫。

2025 年前的關稅環境為診斷設備製造商、經銷商和醫療採購機構帶來了更大的複雜性。進口關稅的增加和關稅分類的變化可能會推高設備、試劑盒和試劑的採購成本，迫使各機構重新評估籌資策略並實現供應商多元化。為此，一些製造商正在加快生產本地化進程，並對替代供應商進行認證，以降低風險並維持穩定的利潤率。

基於細分的洞察，了解產品架構、最終用戶需求和應用程式優先順序如何決定部署模式和籌資策略。

詳細的細分分析揭示了不同產品類型、最終用戶和應用場景下技術採納和使用模式的顯著差異。在產品類型方面，諸如自動化ELISA分析儀、免疫檢測分析儀和PCR系統等儀器和設備通常優先應用於高通量診斷檢查室和大規模醫院系統，因為這些場所對處理能力、準確性和與自動化檢測系統的整合度要求極高。相較之下，試劑盒和檢測方法（例如ELISA試劑盒、PCR檢測套組和快速檢測套組）的應用範圍更為廣泛。 ELISA和PCR試劑盒通常用於支援集中式檢查室工作流程，而快速檢測套組則可用於門診和醫院分診等場景，幫助患者做出決策。

美洲、歐洲、中東和非洲以及亞太地區的區域診斷環境和醫療保健系統特徵影響部署、報銷和部署策略。

區域趨勢對早產和胎膜早破檢測的引入路徑、報銷機制以及與臨床流程的整合有顯著影響。在美洲，臨床決策受到公立和私立保險公司、區域核心醫療機構以及醫院和檢查室之間高度整合的限制。這種環境有利於擴充性的設備平台和檢驗的試劑盒在整合的醫療保健系統中推廣應用，同時也支持學術機構進行以本地為中心的創新。

競爭、夥伴關係策略和基於證據的差異化將決定哪些公司在早產和胎膜早破診斷領域的創新中處於主導。

早產和胎膜早破檢測領域的競爭動態由成熟的診斷公司、專業試劑供應商以及將照護現場(PoC) 技術推向市場的敏捷創新者共同塑造。現有儀器製造商繼續在平台可靠性、與檢查室自動化系統的兼容性以及全球服務網路方面競爭，而新參與企業則透過獨特的檢測化學、簡化的使用者介面和快速部署模式來脫穎而出。儀器製造商和檢測開發商之間的策略合作和共同開發契約日益增多，這有助於加快市場共用速度並共享監管合規流程。

針對診斷設備製造商和醫療保健領導者的可操作策略重點，重點在於檢驗、彈性供應鏈、靈活的商業模式和支付方合作關係。

產業領導者應優先考慮多管齊下的策略，將產品創新與臨床檢驗、供應鏈穩健性和支付方合作結合。首先，投資可操作的臨床研究至關重要，這些研究應能證明診斷結果如何改變行政決策並改善母嬰結局，從而獲得臨床醫生的支持並推動醫保報銷方面的討論。這些研究的設計應充分考慮真實世界的臨床工作流程，並納入多中心合作，以提高研究結果的普遍性。

採用嚴謹的調查方法，結合專家的直接訪談、技術文件和臨床文獻的整合，以檢驗診斷效能和實施注意事項。

本分析整合了同行評審的臨床文獻、監管指導文件、業界公開的技術規格以及對臨床醫生、實驗室管理人員和採購負責人的訪談。該方法優先採用「三角驗證」策略，將分析性能的證據與源自真實臨床實踐的臨床效用和操作實施方面的見解相結合。在監管指導文件相關的情況下，其解讀著重於其如何滿足檢驗要求和上市後監測，而非特定司法管轄區的合規性檢查清單。

概述診斷技術創新、對證據的期望以及將決定早產和胎膜早破檢測未來方向的營運重點。

總而言之，在技術進步、對更高證據水平的期望以及營運需求的推動下，早產和胎膜早破檢測的診斷格局正在迅速發展。臨床醫生和檢查室管理人員越來越傾向於尋求不僅分析可靠，而且具有顯著臨床意義並能無縫融入臨床流程的診斷方法。與供應鏈連續性和定價相關的成本壓力正在促使採購和合約設計進行策略性調整，從而影響部署和檢驗計劃。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：早產及胎膜早破檢測市場：依產品類型分類

  • 設備/器材
    • 自動ELISA分析儀
    • 免疫檢測裝置
    • PCR系統
  • 試劑盒和檢測試劑盒
    • ELISA試劑盒
    • PCR檢測套組
    • 快速檢測套組
  • 試劑和耗材
    • 抗體
    • 緩衝液和培養基
    • 酵素和探針

第9章：早產及胎膜早破檢測市場：依技術分類

  • 生化試驗
  • 分子診斷
  • 生物物理和成像診斷方法

第10章：生物標記在早產和胎膜早破檢測的市場

  • 蛋白質生物標記
  • 遺傳和基因組標記
  • 微生物和感染疾病標記物

第11章：早產和胎膜早破檢測市場：依最終用戶分類

  • 門診治療
  • 診斷檢查室
  • 醫院和診所
  • 研究機構

第12章：早產及胎膜早破檢測市場：依應用領域分類

  • 診斷
  • 監測
  • 出於研究目的
  • 篩檢

第13章：早產及胎膜早破檢測市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：早產及胎膜早破檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 早產與胎膜早破市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國早產和胎膜早破檢測市場

第17章：中國早產和胎膜早破檢測市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • bioMerieux SA
  • Danaher Corporation
  • Eurofins Scientific SE
  • Hologic, Inc.
  • Qiagen NV
  • Quidel Corporation
  • Revvity, Inc.
  • Rhomed SpA
  • Roche Diagnostics GmbH
  • Sekisui Medical Co., Ltd.
  • Sera Prognostics, Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
Product Code: MRR-42653751E7E1

The Preterm Birth & PROM Testing Market was valued at USD 1.46 billion in 2025 and is projected to grow to USD 1.54 billion in 2026, with a CAGR of 5.62%, reaching USD 2.14 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.46 billion
Estimated Year [2026] USD 1.54 billion
Forecast Year [2032] USD 2.14 billion
CAGR (%) 5.62%

A dynamic introduction to clinical priorities, diagnostic workflows, and operational pressures shaping preterm birth and PROM testing across healthcare settings

Preterm birth and premature rupture of membranes (PROM) testing sit at the intersection of obstetrics, neonatal care, and diagnostic innovation. Clinicians increasingly rely on objective biomarkers and improved testing workflows to make time-sensitive decisions that affect maternal and neonatal outcomes. Meanwhile, laboratory directors and procurement teams face mounting pressure to balance accuracy, throughput, and cost while integrating new platforms into existing diagnostic ecosystems.

In clinical practice, early and precise identification of PROM and imminent preterm delivery can materially influence treatment pathways, including administration of corticosteroids, antibiotics, tocolytics, and decisions regarding transfer to higher-acuity centers. As a result, innovations that deliver rapid, reliable results in near-patient and laboratory settings are drawing significant attention from clinical leaders. Concurrently, regulatory scrutiny and evidence-based guideline updates are reshaping the expectations for test validation, clinical utility demonstrations, and post-market surveillance.

From an operational perspective, the diagnostic landscape is evolving toward modular workflows that support high-volume laboratory automation as well as decentralized testing at ambulatory and hospital sites. Cross-disciplinary collaboration among obstetricians, perinatologists, laboratorians, and hospital administrators is becoming central to implementing testing protocols that are clinically meaningful and operationally sustainable. Taken together, these dynamics underscore the critical role of diagnostic testing innovation in improving prenatal care pathways and reducing downstream neonatal complications.

How recent technological, evidence, and supply chain shifts are reshaping diagnostic strategies for detecting preterm birth risks and premature rupture of membranes

Recent years have seen a transformative shift in how preterm birth risk and PROM are identified, monitored, and managed. Advances in molecular diagnostics, immunoassays, and point-of-care technologies have enabled faster turnaround times without sacrificing analytical performance. Concurrently, digital health platforms and laboratory information systems are improving data integration, enabling clinicians to combine biomarker results with electronic health record trends and decision support algorithms. These developments have collectively raised clinician expectations for rapid, actionable diagnostic outputs.

Moreover, the diagnostic community has moved toward greater emphasis on clinical utility and pragmatic validation studies. Rather than relying solely on laboratory performance metrics, developers and adopters increasingly demand real-world evidence that links test results to measurable changes in patient management and outcomes. This shift has prompted closer engagement between test manufacturers and clinical investigators to design studies that demonstrate meaningful clinical endpoints.

At the same time, supply chain resilience and reagent sustainability have emerged as strategic priorities. Test developers are investing in reagent stabilization, alternative sourcing strategies, and consumable standardization to reduce operational disruptions. Consequently, adoption decisions now factor not just analytical accuracy but also long-term supply continuity and integration ease. Together, these shifts are reshaping product roadmaps and procurement strategies across clinical and laboratory stakeholders.

Understanding how evolving tariff policies and import cost pressures in 2025 are impacting supply chain resilience, procurement tactics, and deployment timelines for diagnostic testing

The tariff environment entering into 2025 introduced a layer of complexity for diagnostic manufacturers, distributors, and healthcare purchasing organizations. Increased import duties and changes to customs classifications have the potential to elevate landed costs for instruments, kits, and reagents, prompting organizations to reassess sourcing strategies and supplier diversification. In response, some manufacturers accelerated localization of manufacturing or qualified alternate suppliers to mitigate exposure and preserve margin stability.

Procurement leaders have reacted by increasing focus on total cost of ownership and contractual mechanisms that hedge against tariff volatility. For example, multi-year supply agreements with fixed pricing clauses, joint inventory planning, and closer collaboration on demand forecasting have become more common as stakeholders seek predictability. In parallel, diagnostic companies have explored tariff engineering-adjusting bill of materials, assembly processes, or country-of-origin documentation-to minimize the tariff impact without compromising compliance.

Importantly, these tariff-related responses have secondary effects on clinical deployment cycles. Extended lead times for instrument shipments and constrained reagent availability can delay validation activities in diagnostic laboratories and slow rollout of new tests in ambulatory and hospital settings. Consequently, health systems and laboratories are placing greater emphasis on contingency planning and flexible validation protocols so clinical service continuity is preserved when supply chain interruptions occur. These adaptations are reshaping procurement playbooks and innovation timelines across the diagnostic ecosystem.

Segmentation-driven insights into how product architectures, end-user needs, and application priorities determine adoption patterns and procurement strategies

A granular segmentation analysis reveals meaningful differences in technology adoption and usage patterns across product types, end users, and applications. Within product types, instruments and equipment such as automated ELISA analyzers, immunoassay analyzers, and PCR systems are typically prioritized by high-throughput diagnostic laboratories and larger hospital systems where throughput, precision, and integration with laboratory automation are paramount. In contrast, kits and assay formats including ELISA kits, PCR test kits, and rapid test kits serve a broader array of settings; ELISA and PCR kits often underpin centralized laboratory workflows while rapid test kits enable near-patient decision-making in ambulatory care or hospital triage.

Reagents and consumables, encompassing antibodies, buffers and media, and enzymes and probes, represent the recurring operational spend that drives procurement and inventory strategies. End users differ in their procurement and validation imperatives: ambulatory care settings typically prioritize ease of use and rapid turnaround, diagnostic laboratories emphasize throughput and analytical robustness, hospitals and clinics require scalability and compatibility with clinical workflows, and research institutes often seek customizable reagents and the flexibility to support exploratory assays. Applications further segment the demand profile, as diagnostic use cases demand regulatory-grade validation and reproducibility, monitoring applications focus on serial sampling and longitudinal interpretation, research use prioritizes experimental flexibility, and screening requires high throughput, cost-effectiveness, and minimal false-positive rates.

Taken together, the interplay among product architecture, end-user operational constraints, and intended application informs product development priorities, go-to-market segmentation, and the structure of commercial partnerships across the diagnostic value chain.

Regional diagnostic landscapes and healthcare system nuances that shape adoption, reimbursement, and deployment strategies across the Americas, EMEA, and Asia-Pacific

Regional dynamics materially influence diagnostic adoption pathways, reimbursement frameworks, and pathway integration for preterm birth and PROM testing. In the Americas, clinical decision-making is shaped by a mix of private and public payers, regional centers of excellence, and a strong emphasis on hospital and laboratory consolidation. This environment favors scalable instrument platforms and validated kits that can be deployed across integrated health systems, while also supporting localized innovation in academic centers.

Europe, Middle East & Africa features diverse regulatory landscapes and variable healthcare funding models, which create heterogenous adoption rates across countries. In many Western European markets, centralized reimbursement and robust clinical guidelines accelerate uptake of validated diagnostic tests, whereas in other parts of the region, constrained healthcare budgets and logistical barriers prioritize low-cost rapid tests and locally adaptable reagent solutions. Additionally, regional collaborations and cross-border research partnerships are playing an increasing role in evidence generation and guideline harmonization.

Asia-Pacific encompasses a fast-adopting mix of high-income healthcare systems and large emerging markets, where rapid urbanization and expanding prenatal care access drive demand for both high-throughput laboratory solutions and decentralized testing models. Local manufacturing hubs and government-supported initiatives aimed at strengthening perinatal care infrastructures are accelerating product localization and public-private partnerships. Across all regions, stakeholders are converging on the need for evidence of clinical utility, seamless integration into care pathways, and resilient supply chains to ensure continuous access to critical diagnostic testing.

Competitive forces, partnership strategies, and evidence-driven differentiation that determine which companies lead in preterm birth and PROM diagnostic innovation

Competitive dynamics in the preterm birth and PROM testing space are shaped by a mix of established diagnostics companies, specialized reagent suppliers, and agile innovators bringing point-of-care capabilities to market. Incumbent instrument manufacturers continue to compete on platform reliability, laboratory automation compatibility, and global service networks, while newer entrants differentiate through niche assay chemistries, simplified user interfaces, and rapid deployment models. Strategic partnerships and co-development agreements between instrumentation firms and assay developers have increased, enabling faster market entry and shared regulatory pathways.

Reagent and consumable suppliers that demonstrate consistent quality, validated supply chains, and packaging formats optimized for clinical laboratories gain preference among procurement teams. Meanwhile, companies that invest in clinical validation programs and publish real-world evidence can accelerate clinician adoption by proving not only analytical accuracy but also measurable impact on care decisions. Additionally, channel dynamics such as distributor relationships, direct sales to hospitals, and laboratory network agreements influence reach and uptake across geographies.

Overall, competitive advantage increasingly depends on the ability to align technical performance with operational resilience and evidence-based clinical value, creating opportunities for firms that can integrate across the diagnostic ecosystem and support customers across the lifecycle from implementation to post-market surveillance.

Actionable strategic priorities for diagnostic manufacturers and healthcare leaders focused on validation, resilient supply chains, flexible commercial models, and payer engagement

Industry leaders should prioritize a multi-pronged strategy that aligns product innovation with clinical validation, supply chain robustness, and payer engagement. First, investing in pragmatic clinical studies that demonstrate how diagnostic results change management decisions and improve maternal and neonatal outcomes will be critical to securing clinician buy-in and supporting reimbursement discussions. These studies should be designed with real-world workflows in mind and incorporate multicenter collaborations to enhance generalizability.

Second, strengthening supply chain resilience through dual sourcing, geographic diversification of manufacturing, and longer-term reagent stability initiatives will reduce operational risk and improve customer confidence. In parallel, offering flexible commercial models-such as reagent-as-a-service, reagent rental agreements for instruments, or bundled implementation packages-can lower adoption barriers for health systems and laboratories.

Third, leaders should engage proactively with payers, guideline-setting bodies, and hospital procurement committees to demonstrate the value proposition beyond test accuracy, highlighting downstream cost avoidance, reduced neonatal morbidity, and improved care pathways where evidence supports those outcomes. Finally, fostering interoperable platforms and open data standards will ease integration with hospital systems and enable value-added analytics that amplify the clinical utility of test results. By pursuing these complementary actions, manufacturers and stakeholders can accelerate adoption while mitigating commercial and operational risks.

A rigorous methodology combining primary expert interviews, technical documentation, and clinical literature synthesis to validate diagnostic performance and implementation considerations

This analysis synthesizes peer-reviewed clinical literature, regulatory guidance documents, industry-available technical specifications, and primary interviews with clinicians, laboratory directors, and procurement professionals. The approach prioritized triangulation, combining evidence of analytical performance with insights about clinical utility and operational implementation drawn from real-world practice. Where regulatory guidance was relevant, interpretations focused on how guidance informs validation needs and post-market surveillance rather than on jurisdiction-specific compliance checklists.

Primary research included structured interviews with subject-matter experts across obstetrics, neonatology, clinical laboratory science, and hospital operations. Secondary research reviewed methodological papers on assay performance, published clinical studies examining outcomes related to PROM and preterm birth diagnostics, and supplier technical documentation that details platform capabilities and consumable requirements. Data synthesis emphasized thematic consistency across sources, and areas of divergent opinion are noted to highlight uncertainties and opportunities for targeted evidence generation.

Limitations of the methodology include variability in study designs and endpoints within the clinical literature, heterogeneity in local adoption pathways across regions, and evolving policy dynamics that may alter procurement incentives. To mitigate these limitations, findings were validated through multiple expert interviews and cross-checked against technical product literature to ensure that practical implementation considerations are well represented.

Concluding synthesis of diagnostic innovation, evidence expectations, and operational priorities that determine the future trajectory of preterm birth and PROM testing

In summary, the diagnostic landscape for preterm birth and PROM testing is undergoing rapid evolution driven by technological advances, higher evidentiary expectations, and operational imperatives. Clinicians and laboratory leaders are seeking diagnostics that deliver not only analytical reliability but also demonstrable clinical impact and seamless integration into care pathways. Supply chain continuity and tariff-related cost pressures are prompting strategic shifts in sourcing and contract design, affecting timelines for deployment and validation.

Segmentation insight indicates that instruments and high-throughput platforms will remain central to hospital and laboratory strategies, while rapid and point-of-care kits will expand access in ambulatory settings and emergency triage. Reagents and consumables continue to shape recurring procurement dynamics, and applications spanning diagnosis, monitoring, research use, and screening create differentiated requirements for validation and workflow integration. Regionally, the interplay of reimbursement, regulatory frameworks, and local manufacturing capacity will continue to produce heterogeneous adoption pathways.

For stakeholders intent on advancing prenatal diagnostics, the clear priorities are robust clinical validation, resilient and transparent supply models, and closer engagement with payers and guideline committees. These priorities will determine which innovations translate into sustainable clinical uptake and improved maternal and neonatal outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Preterm Birth & PROM Testing Market, by Product Type

  • 8.1. Instruments & Equipment
    • 8.1.1. Automated Elisa Analyzers
    • 8.1.2. Immunoassay Analyzers
    • 8.1.3. Pcr Systems
  • 8.2. Kits & Assay Kits
    • 8.2.1. Elisa Kits
    • 8.2.2. Pcr Test Kits
    • 8.2.3. Rapid Test Kits
  • 8.3. Reagents & Consumables
    • 8.3.1. Antibodies
    • 8.3.2. Buffers & Media
    • 8.3.3. Enzymes & Probes

9. Preterm Birth & PROM Testing Market, by Technology

  • 9.1. Biochemical Assays
  • 9.2. Molecular Diagnostics
  • 9.3. Biophysical & Imaging Methods

10. Preterm Birth & PROM Testing Market, by Biomarker

  • 10.1. Protein Biomarkers
  • 10.2. Genetic And Genomic Markers
  • 10.3. Microbial And Infection Markers

11. Preterm Birth & PROM Testing Market, by End User

  • 11.1. Ambulatory Care
  • 11.2. Diagnostic Laboratories
  • 11.3. Hospitals & Clinics
  • 11.4. Research Institutes

12. Preterm Birth & PROM Testing Market, by Application

  • 12.1. Diagnosis
  • 12.2. Monitoring
  • 12.3. Research Use
  • 12.4. Screening

13. Preterm Birth & PROM Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Preterm Birth & PROM Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Preterm Birth & PROM Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Preterm Birth & PROM Testing Market

17. China Preterm Birth & PROM Testing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. bioMerieux SA
  • 18.7. Danaher Corporation
  • 18.8. Eurofins Scientific SE
  • 18.9. Hologic, Inc.
  • 18.10. Qiagen N.V.
  • 18.11. Quidel Corporation
  • 18.12. Revvity, Inc.
  • 18.13. Rhomed S.p.A.
  • 18.14. Roche Diagnostics GmbH
  • 18.15. Sekisui Medical Co., Ltd.
  • 18.16. Sera Prognostics, Inc.
  • 18.17. Siemens Healthineers AG
  • 18.18. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PRETERM BIRTH & PROM TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOMARKER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES PRETERM BIRTH & PROM TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA PRETERM BIRTH & PROM TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY AUTOMATED ELISA ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY AUTOMATED ELISA ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY AUTOMATED ELISA ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PCR SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PCR SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PCR SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ELISA KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ELISA KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ELISA KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PCR TEST KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PCR TEST KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PCR TEST KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RAPID TEST KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RAPID TEST KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RAPID TEST KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BUFFERS & MEDIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BUFFERS & MEDIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BUFFERS & MEDIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ENZYMES & PROBES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ENZYMES & PROBES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ENZYMES & PROBES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOPHYSICAL & IMAGING METHODS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOPHYSICAL & IMAGING METHODS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOPHYSICAL & IMAGING METHODS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PROTEIN BIOMARKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PROTEIN BIOMARKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PROTEIN BIOMARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY GENETIC AND GENOMIC MARKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY GENETIC AND GENOMIC MARKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY GENETIC AND GENOMIC MARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY MICROBIAL AND INFECTION MARKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY MICROBIAL AND INFECTION MARKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY MICROBIAL AND INFECTION MARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY DIAGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY DIAGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RESEARCH USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RESEARCH USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RESEARCH USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 174. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 175. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 176. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 178. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 198. G7 PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. G7 PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. G7 PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 201. G7 PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 202. G7 PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 203. G7 PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 204. G7 PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 205. G7 PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. G7 PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 207. NATO PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. NATO PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. NATO PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 210. NATO PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 211. NATO PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 212. NATO PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 213. NATO PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 214. NATO PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. NATO PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES PRETERM BIRTH & PROM TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA PRETERM BIRTH & PROM TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)